Drug transporters in the lung - Do they play a role in the biopharmaceutics of inhaled drugs?

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2240-2255

  Cynthia, Bosquillon ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Calu 3 cells; Cell culture; Drug inhalation; Isolated perfused lungs; Multidrug resistance transporters; Organic anion transporters; Organic cation transporters; Peptide transporters; Permeability; Pulmonary delivery

Indexed keywords

ABC TRANSPORTER; ACETYLCYSTEINE; BECLOMETASONE DIPROPIONATE; BREAST CANCER RESISTANCE PROTEIN; BUDESONIDE; CICLESONIDE; CIPROFLOXACIN; DEXAMETHASONE; DIGOXIN; ELACRIDAR; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; GF 120918A; GLYCOPROTEIN P; IPRATROPIUM BROMIDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MOMETASONE FUROATE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER; PENTAMIDINE; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; SALBUTAMOL; TOBRAMYCIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINBLASTINE;

APICAL MEMBRANE; ASTHMA; BRONCHUS MUCOSA; CELL GROWTH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYTOTOXICITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSPORT; GASTROINTESTINAL TRACT; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CLEARANCE; LUNG PARENCHYMA; MICROARRAY ANALYSIS; NOSE POLYP; PERMEABILITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SMOKING; TISSUE DISTRIBUTION;

EID: 77951277135     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21995     Document Type: Review

References (138)

1. Ayrton A, Morgan P. 2008. Role of transport proteins in drug discovery and development: A pharmaceutical perspective. Xenobiotica 38:676-708.
2. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B. 2008. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13:379-393.
3. Forbes B, Ehrhardt C. 2005. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 60:193-205. (Pubitemid 40804561)
4. Sporty JL, Horálková L, Ehrhardt C. 2008. In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin Drug Metab Toxicol 4:333-345.
5. Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. 2006. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm Res 23: 1482-1490. (Pubitemid 43993811)
6. Forbes B, Shah A, Martin GP, Lansley AB. 2003. The human bronchial epithelial cell line 16HBE14o- as a model system of the airways for studying drug transport. Int J Pharm 12:161-167. (Pubitemid 36507042)
7. Lin H, Li H, Cho HJ, Bian S, Roh HJ, Lee MK, Kim JS, Chung SJ, Shim CK, Kim DD. 2007. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sci 96:341-350. (Pubitemid 46363565)
8. Tronde A, Bosquillon C, Forbes B. 2008. The isolated perfused lung. In: Ehrhardt C, Kim KJ, editors. Preclinical biopharmaceutics - In situ, in vitro and in silico tools for drug absorption studies. New York: Springer. pp 135-163.
9. Madlova M, Bosquillon C, Asker D, Dolezal P, Forbes B. 2009. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. J Pharm Pharmacol 61:293-301.
10. Francombe D, Taylor G, Taylor S, Somers G, Edwards C, Gumbleton M. 2008. Functional role of P-gp efflux in limiting pulmonary drug absorption within an intact lung: Application of an isolated perfused rat lung model. Proc Resp Drug Deliv 2:461-464.
11. Linder A, Friedel G, Fritz P, Kivistö KT, McClellan M, Toomes H. 1996. The ex-vivo isolated, perfused human lung model: Description and potential applications. Thorac Cardiovasc Surg 44:140-146. (Pubitemid 26246968)
12. Freiwald M, Valotis A, Kirschbaum A, McClellan M, Müller T, Fritz P, Friedel G, Thomas M, Höggger P. 2005. Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model. Respir Res 6:21-33.
13. van der Deen M, Marks H, Willemse BW, Postma DS, Müller M, Smit EF, Scheffer GL, Scheper RJ, de Vries EG, Timens W. 2006. Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch 449:682-688.
14. van der Deen M, de Vries EG, Visserman H, Zandbergen W, Postma DS, Timens W, Timmer-Bosscha H. 2007. Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. J Biochem Mol Toxicol 21:243-251. (Pubitemid 350006281)
15. Steiner E, Holzmann K, Elbling L, Micksche M, Berger W. 2006. Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 7:923-934. (Pubitemid 44234394)
16. Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9:105-127.
17. Leslie EM, Deeley RG, Cole SP. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
18. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55:3-29.
19. van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS. 2005. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 6:59. (Pubitemid 41410176)
20. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. 2006. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3:62-69. (Pubitemid 43331752)
21. Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G. 2003. Real-time reverse transcription-PCR expression profiling of the complete human ATPbinding cassette transporter superfamily in various tissues. Clin Chem 49:230-238. (Pubitemid 36143443)
22. Lechapt-Zalcman E, Hurbain I, Lacave R, Commo F, Urban T, Antoine M, Milleron B, Bernaudin JF. 1997. MDR1-Pgp 170 expression in human bronchus. Eur Respir J 10:1837-1843. (Pubitemid 27368379)
23. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG. 2006. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica 36:963-988. (Pubitemid 44844110)
24. Scheffer GL, Pijnenborg AC, Smit EF, Müller M, Postma DS, Timens W, van der Valk P, de Vries EG, Scheper RJ. 2002. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 55:332-339.
25. van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ, Pinedo HM, Scheper RG. 1990. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1:56-64.
26. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287. (Pubitemid 20266126)
27. Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, GumbletonM. 2003. Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther 304:441-452.
28. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. 1989. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346-1350. (Pubitemid 19071705)
29. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD. 2002. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838-844. (Pubitemid 34671097)
30. 99mTc-sestamibi radioaerosol is delayed in healthy cigarette smokers. Br J Clin Pharmacol 65:611-614.
31. Hendrikse NH, Franssen EJ, van der Graaf WT, Meijer C, Piers DA, Vaalburg W, de Vries EG. 1998. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 77:353-358. (Pubitemid 28044036)
32. Blokzijl H, Vander Borght S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. 2007. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 13:710-720. (Pubitemid 46909985)
33. Henriksson G, Norlander T, Zheng X, Stierna P, Westrin KM. 1997. Expression of P-glycoprotein 170 in nasal mucosa may be increased with topical steroids. Am J Rhinol 11:317-321. (Pubitemid 27392415)
34. Demeule M, Jodoin J, Beaulieu E, Brossard M, Béliveau R. 1999. Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 442:208-214. (Pubitemid 29070835)
35. Dinis-Oliveira RJ, Duarte JA, Remião F, Sánchez-Navarro A, Bastos ML, Carvalho F. 2006. Single high dose dexamethasone treatment decreases the pathological score and increases the survival rate of paraquat-intoxicated rats. Toxicology 227:73-85. (Pubitemid 44402856)
36. Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, Lenoir G. 1997. Induction by antitumoral drugs of proteins that functionally complement CFTR: A novel therapy for cystic fibrosis? Lancet 350:711-712.
37. Naumann N, Siratska O, Gahr M, Rösen-Wolff A. 2005. Pglycoprotein expression increases ATP release in respiratory cystic fibrosis cells. J Cyst Fibros 4:157-168. (Pubitemid 41200477)
38. Ye S, MacEachran DP, Hamilton JW, O'Toole GA, Stanton BA. 2008. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.AmJ Physiol Cell Physiol 295:C807-C818.
39. Florea BI, van der Sandt IC, Schrier SM, Kooiman K, Deryckere K, de Boer AG, Junginger HE, Borchard G. 2001. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu- 3). Br J Pharmacol 134:1555-1563. (Pubitemid 33131907)
40. Hamilton KO, Backstrom G, Yazdanian MA, Audus KL. 2001. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J Pharm Sci 90:647-658. (Pubitemid 32378386)
41. Endter S, Francombe D, Ehrhardt C, Gumbleton M. 2009. RTPCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol 61:583-591.
42. Brillault J, De Castro WV, Harnois T, Kitzis A, Olivier JC, Couet W. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother 53:1457-1462.
43. Ehrhardt C, Kneuer C, Laue M, Schaefer UF, Kim KJ, Lehr CM. 2003. 16HBE14o- human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolin-1. Pharm Res 20:545-551. (Pubitemid 36438896)
44. Lehmann T, Köhler C, Weidauer E, Taege C, Foth H. 2001. Expression of MRP1 and related transporters in human lung cells in culture. Toxicology 167:59-72. (Pubitemid 32830947)
45. Endter S, Becker U, Daum N, Huwer H, Lehr CM, Gumbleton M, Ehrhardt C. 2007. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res 328: 77-84. (Pubitemid 46411916)
46. Cavet ME, West M, Simmons NL. 1997. Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells. Antimicrob Agents Chemother 41:2693-2698. (Pubitemid 27524741)
47. Patel J, Pal D, Vangal V, Gandhi M, Mitra AL. 2002. Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: Modulation of Pglycoprotein activity. Pharm Res 19:1696-1703. (Pubitemid 35305522)
48. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. 1993. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
49. Ehrhardt C, Collnot EM, Baldes C, Becker U, Laue M, Kim KJ, Lehr CM. 2006. Towards an in vitro model of cystic fibrosis small airway epithelium: Characterisation of the human bronchial epithelial cell line CFBE41o-. Cell Tissue Res 323:405-415. (Pubitemid 43228096)
50. Steimer A, Franke H, Haltner-Ukomado E, Laue M, Ehrhardt C, Lehr CM. 2007. Monolayers of porcine alveolar epithelial cells in primary culture as an in vitro model for drug absorption studies. Eur J Pharm Biopharm 66:372-382. (Pubitemid 46756213)
51. Kuhlmann O, Hofmann HS, Müller SP, Weiss M. 2003. Pharmacokinetics of idarubicin in the isolated perfused rat lung: Effect of cinchonine and rutin. Anticancer Drugs 14:411-416.
52. Roerig DL, Audi SH, Ahlf SB. 2004. Kinetic characterization of P-glycoprotein-mediated efflux of rhodamine 6G in the intact rabbit lung. Drug Metab Dispos 32:953-958.
53. Tronde A, Nordén B, Jeppsson AB, Brunmark P, Nilsson E, Lennernäs H, Bengtsson UH. 2003. Drug absorption from the isolated perfused rat lung - Correlations with drug physicochemical properties and epithelial permeability. J Drug Target 11:61-74. (Pubitemid 36527397)
54. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. 2000. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011-2021. (Pubitemid 30386505)
55. Manford F, Riffo-Vasquez Y, Spina D, Page CP, Hutt AJ, Moore V, Johansson F, Forbes B. 2008. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice. J Pharm Pharmacol 60:1305-1310.
56. Funakoshi S, Murakami T, Yumoto R, Kiribayashi Y, Takano M. 2005. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J Pharm Sci 94:1196-1203. (Pubitemid 40904184)
57. Hagenbuch B, Gui C. 2008. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
58. Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. 2008. MRP class of human ATP binding cassette (ABC) transporters: Historical background and new research directions. Xenobiotica 38:833-862.
59. Jedlitschky G, Hoffmann U, Kroemer HK. 2006. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2:351-366. (Pubitemid 46141403)
60. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547. (Pubitemid 27355505)
61. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ. 1996. Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247. (Pubitemid 26111082)
62. Bréchot JM, Hurbain I, Fajac A, Daty N, Bernaudin JF. 1998. Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem Cytochem 46: 513-517. (Pubitemid 28158471)
63. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH. 2002. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41:65-74.
64. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. 2002. Organ distribution of multidrug resistance proteins 1,2 and 3 (Mrp1, 2, and 3)mRNAand hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 300:97-104.
65. Maher JM, Slitt AL, Cherrington NJ, Cheng X, Klaassen CD. 2005. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos 33:947-955. (Pubitemid 41002776)
66. Lehmann T, Torky AR, Stehfest E, Hofmann S, Foth H. 2005. Expression of lung resistance-related protein, LRP, and multi-drug resistance-related protein, MRP1, in normal human lung cells in long-term cultures. Arch Toxicol 79:600-609. (Pubitemid 41483268)
67. Torky AR, Stehfest E, Viehweger K, Taege C, Foth H. 2005. Immuno-histochemical detection of MRPs in human lung cells in culture. Toxicology 207: 437-450. (Pubitemid 40138940)
68. Torky A, Raemisch A, Glahn F, Foth H. 2008. Arachidonic acid pathway activates multidrug resistance related protein in cultured human lung cells. Arch Toxicol 82:323-332. (Pubitemid 351692071)
69. Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL. 2001. Multidrug resistance-associated protein- 1 functional activity in Calu-3 cells. J Pharmacol Exp Ther 298:1199-1205. (Pubitemid 32761940)
70. van der Deen M, Homan S, Timmer-Bosscha H, Scheper RJ, Timens W, Postma DS, de Vries EG. 2008. Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells. Int J Chron Obstruct Pulmon Dis 3:469-475.
71. Patel LN, Uchiyama T, Kim KJ, Borok Z, Crandall ED, Shen WC, Lee VH. 2008. Molecular and functional expression of multidrug resistance-associated protein-1 in primary cultured rat alveolar epithelial cells. J Pharm Sci 97:2340-2349.
72. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. 2009. ABCG2: A perspective. Adv Drug Deliv Rev 61:3-13.
73. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 95:15665-15670. (Pubitemid 29018757)
74. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE. 2006. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235:84-92.
75. Koepsell H, Lips K, Volk C. 2007. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251. (Pubitemid 46876495)
76. Ciarimboli G. 2008. Organic cation transporters. Xenobiotica 38:936-971.
77. Choi MK, Song IS. 2008. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 23:243-253.
78. Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, Miska D, Ermert L, Kummer W, Koepsell H. 2005. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol 33:79-88. (Pubitemid 40961017)
79. Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, Wanner A. 2007. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol 36:53-60. (Pubitemid 46067707)
80. Horvath G, Mendes ES, Schmid N, Schmid A, Conner GE, Salathe M, Wanner A. 2007. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. J Allergy Clin Immunol 120:1103-1109. (Pubitemid 350029910)
81. Lips KS, Lührmann A, Tschernig T, Stoeger T, Alessandrini F, Grau V, Haberberger RV, Koepsell H, Pabst R, Kummer W. 2007. Down-regulation of the non-neuronal acetylcholine synthesis and release machinery in acute allergic airway inflammation of rat and mouse. Life Sci 80:2263-2269. (Pubitemid 46830783)
82. Kummer W, Wiegand S, Akinci S, Wessler I, Schinkel AH, Wess J, Koepsell H, Haberberger RV, Lips KS. 2006. Role of acetylcholine and polyspecific cation transporters in serotonin- induced bronchoconstriction in the mouse. Respir Res 7:65. (Pubitemid 43778774)
83. Kummer W, Lips KS, Pfeil U. 2008. The epithelial cholinergic system of the airways. Histochem Cell Biol 130:219-234.
84. Ehrhardt C, Kneuer C, Bies C, Lehr CM, Kim KJ, Bakowsky U. 2005. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther 18:165-170. (Pubitemid 40222110)
85. Shen J, Elbert KJ, Yamashita F, Lehr CM, Kim KJ, Lee VHL. 1999. Organic cation transport in rabbit alveolar epithelial cell monolayers. Pharm Res 16:1280-1287. (Pubitemid 29393619)
86. Glube N, Closs E, Langguth P. 2007. OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol Pharm 4:160-168. (Pubitemid 46302138)
87. Daniel H, Kottra G. 2004. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch 447:610-618.
88. Berger UV, Hediger MA. 1999. Distribution of peptide transporter PEPT2mRNAin the rat nervous system. Anat Embryol (Berl) 199:439-449.
89. Groneberg DA, Döring F, Theis S, Nickolaus M, Fischer A, Daniel H. 2002. Peptide transport in the mammary gland: Expression and distribution of PEPT2 mRNA and protein. Am J Physiol Endocrinol Metab 282:E1172-E1179.
90. Lu H, Klaassen C. 2006. Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents. Peptides 27:850-857.
91. Zhu T, Chen XZ, Steel A, Hediger MA, Smith DE. 2000. Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2. Pharm Res 17:526-532.
92. Yang CY, Dantzig AH, Pidgeon C. 1999. Intestinal peptide transport systems and oral drug availability. Pharm Res 16:1331-1343.
93. Groneberg DA, Fischer A, Chung KF, Daniel H. 2004. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am J Respir Cell Mol Biol 30:251-260.
94. Boll M, Herget M, Wagener M, Weber WM, Markovich D, Biber J, Clauss W, Murer H, Daniel H. 1996. Expression cloning and functional characterization of the kidney cortex high-affinity proton-coupled peptide transporter. Proc Natl Acad Sci 93:284-289.
95. Döring F, Walter J, Will J, Föcking M, Boll M, Amasheh S, Clauss W, Daniel H. 1998. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest 101: 2761-2767.
96. Saito H, Terada T, Okuda M, Sasaki S, Inui K. 1996. Molecular cloning and tissue distribution of rat peptide transporter PEPT2. Biochim Biophys Acta 1280:173-177.
97. Groneberg DA, Nickolaus M, Springer J, Döring F, Daniel H, Fischer A. 2001. Localization of the peptide transporter PEPT2 in the lung: Implications for pulmonary oligopeptide uptake. Am J Pathol 158:707-714.
98. Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA. 1994. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368:563-566. (Pubitemid 24118776)
99. Saito H, Okuda M, Terada T, Sasaki S, Inui K. 1995. Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther 275:1631-1637.
100. Yang XD, Ma JY, Barger MW, Ma JK. 2002. Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages. Pharm Res 19:825-831.
101. Søndergaard HB, Brodin B, Nielsen CU. 2008. hPEPT1 is responsible for uptake and transport of Gly-Sar in the human bronchial airway epithelial cell-line Calu-3. Pflugers Arch 456:611-622.
102. Groneberg DA, Eynott PR, Döring F, Dinh QT, Oates T, Barnes PJ, Chung KF, Daniel H, Fischer A. 2002. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax 57:55-60.
103. Granillo OM, Brahmajothi MV, Li S, Whorton AR, Mason SN, McMahon TJ, Auten RL. 2008. Pulmonary alveolar epithelial uptake of S-nitrosothiols is regulated by L-type amino acid transporter. Am J Physiol Lung Cell Mol Physiol 295:L38-L43.
104. Bahadduri PM, D'Souza VM, Pinsonneault JK, Sadée W, Bao S, Knoell DL, Swaan PW. 2005. Functional characterization of the peptide transporter PEPT2 in primary cultures of human upper airway epithelium. Am J Respir Cell Mol Biol 32: 319-325.
105. Pinsonneault J, Nielsen CU, Sadée W. 2004. Genetic variants of the human H+/dipeptide transporter PET2: Analysis of haplotype functions. J Pharmacol Exp Ther 311:1088-1096.
106. Yamashita F, Kim KJ, Lee VH. 1998. Dipeptide uptake and transport characteristics in rabbit tracheal epithelial cell layers cultured at an air interface. Pharm Res 15:979-983.
107. Miyazaki H, Sekine T, Endou H. 2004. The multispecific organic anion transporter family: Properties and pharmacological significance. Trends Pharmacol Sci 25:654-662.
108. Anzai N, Kanai Y, Endou H. 2006. Organic anion transporter family: Current knowledge. J Pharmacol Sci 100:411-426.
109. Hosoyamada M, Sekine T, Kanai Y, Endou H. 1999. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276:F122-F128. (Pubitemid 29061732)
110. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H. 2000. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 275:4507-4512.
111. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286. (Pubitemid 32385197)
112. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. 1997. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272:18526-18529.
113. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H. 1998. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429:179-182.
114. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H. 1999. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274: 13675-13680.
115. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T. 2002. Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol 62:7-14.
116. Youngblood GL, Sweet DH. 2004. Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney. Am J Physiol Renal Physiol 287:F236-F244.
117. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. 2004. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171-179.
118. Shitara Y, Sato H, Sugiyama Y. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723.
119. Poirier A, Funk C, Lavé T, Noé J. 2007. New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Dev 10:74-83.
120. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260.
121. König J, Cui Y, Nies AT, Keppler D. 2000. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278: G156-G164.
122. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. 2002. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16:2283-2296.
123. Suzuki T, Onogawa T, Asano N, Mizutamari H, Mikkaichi T, Tanemoto M, Abe M, Satoh F, Unno M, Nunoki K, Suzuki M, Hishinuma T, Goto J, Shimosegawa T, Matsuno S, Ito S, Abe T. 2003. Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol Endocrinol 17:1203-1215. (Pubitemid 36819945)
124. Lee SY, Williamson B, Caballero OL, Chen YT, Scanlan MJ, Ritter G, Jongeneel CV, Simpson AJ, Old LJ. 2004. Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun 4:13.
125. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. 2001. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
126. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T. 2003. Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol 285:F1188-F1197.
127. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T. 2001. Identification of thyroid hormone transporters in humans: Different molecules are involved in a tissue-specific manner. Endocrinology 142:2005-2012.
128. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T. 2000. Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun 275:831-838.
129. Cooray HC, Shahi S, Cahn AP, van Veen HW, Hladky SB, Barrand MA. 2006. Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531:25-33.
130. Dilger K, Schwab M, Fromm MF. 2004. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10:578-583.
131. Arya V, Issar M, Wang Y, Talton JD, Hochhaus G. 2005. Brain permeability of inhaled corticosteroids. J Pharm Pharmacol 57:1159-1167.
132. Valenzuela B, Nácher A, Ruiz-Carretero P, Martín-Villodre A, López-Carballo G, Barettino D. 2004. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci 93: 1641-1648.
133. Akan I, Akan S, Akca H, Savas B, Ozben T. 2004. N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance. Eur J Clin Invest 34:683-689.
134. Banerjee SK, Jagannath C, Hunter RL, Dasgupta A. 2000. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci 67:2011-2016.
135. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y. 2007. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
136. Marquez B, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2009. Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: Studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother 53:2410-2416.
137. Hirano T, Yasuda S, Osaka Y, Asari M, Kobayashi M, Itagaki S, Iseki K. 2008. The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo. Int J Pharm 351:113-118.
138. Ming X, Ju W, Wu H, Tidwell RR, Hall JE, Thakker DR. 2009. Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos 37:424-430.